SG11201509265SA - Avoiding narcolepsy risk in influenza vaccines - Google Patents
Avoiding narcolepsy risk in influenza vaccinesInfo
- Publication number
- SG11201509265SA SG11201509265SA SG11201509265SA SG11201509265SA SG11201509265SA SG 11201509265S A SG11201509265S A SG 11201509265SA SG 11201509265S A SG11201509265S A SG 11201509265SA SG 11201509265S A SG11201509265S A SG 11201509265SA SG 11201509265S A SG11201509265S A SG 11201509265SA
- Authority
- SG
- Singapore
- Prior art keywords
- narcolepsy
- avoiding
- risk
- influenza vaccines
- influenza
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361822228P | 2013-05-10 | 2013-05-10 | |
| US201361859113P | 2013-07-26 | 2013-07-26 | |
| US201361862807P | 2013-08-06 | 2013-08-06 | |
| EP13181429 | 2013-08-23 | ||
| EP14158999 | 2014-03-11 | ||
| PCT/EP2014/059672 WO2014180999A1 (en) | 2013-05-10 | 2014-05-12 | Avoiding narcolepsy risk in influenza vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201509265SA true SG11201509265SA (en) | 2015-12-30 |
Family
ID=51660716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201509265SA SG11201509265SA (en) | 2013-05-10 | 2014-05-12 | Avoiding narcolepsy risk in influenza vaccines |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20140335116A1 (ja) |
| EP (1) | EP2801372A3 (ja) |
| JP (1) | JP2016521282A (ja) |
| KR (1) | KR20160030097A (ja) |
| CN (1) | CN105828835A (ja) |
| AU (1) | AU2014264501A1 (ja) |
| BR (1) | BR112015028314A2 (ja) |
| CA (1) | CA2911296A1 (ja) |
| MX (1) | MX2015015428A (ja) |
| SG (1) | SG11201509265SA (ja) |
| WO (1) | WO2014180999A1 (ja) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140335116A1 (en) | 2013-05-10 | 2014-11-13 | Novartis Ag | Avoiding narcolepsy risk in influenza vaccines |
| US20210188983A1 (en) * | 2016-02-18 | 2021-06-24 | Universite De Montpellier | Polypeptides for preparing drug conjugates capable of promoting apoptosis in a cell expressing an orexin receptor |
| US11428638B2 (en) | 2018-01-12 | 2022-08-30 | The Regents Of The University Of California | Spectroscopic biological material characterization |
| CN111803625B (zh) * | 2020-09-09 | 2020-12-18 | 天津中逸安健生物科技有限公司 | 一种亚单位流感疫苗裂解剂及其应用 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0114787B1 (de) | 1983-01-25 | 1991-09-25 | Ciba-Geigy Ag | Neue Peptidderivate |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| HU212924B (en) | 1989-05-25 | 1996-12-30 | Chiron Corp | Adjuvant formulation comprising a submicron oil droplet emulsion |
| US5936076A (en) | 1991-08-29 | 1999-08-10 | Kirin Beer Kabushiki Kaisha | αgalactosylceramide derivatives |
| AU5543294A (en) | 1993-10-29 | 1995-05-22 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
| DE19612966B4 (de) | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
| DE19612967A1 (de) | 1996-04-01 | 1997-10-02 | Behringwerke Ag | Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren |
| TW570803B (en) | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
| US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
| US20030130212A1 (en) | 1999-01-14 | 2003-07-10 | Rossignol Daniel P. | Administration of an anti-endotoxin drug by intravenous infusion |
| BR0014281A (pt) | 1999-09-24 | 2002-05-21 | Smithkline Beecham Biolog | Vacina contra vìrus de gripe intranasal |
| EP1260581B1 (en) | 2000-03-03 | 2010-07-07 | Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute | Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell |
| GB0024089D0 (en) | 2000-10-02 | 2000-11-15 | Smithkline Beecham Biolog | Novel compounds |
| AR032575A1 (es) | 2001-02-23 | 2003-11-12 | Smithkline Beecham Biolog | Uso de una preparacion antigenica de gripe para la fabricacion de una vacuna intradermica de la gripe y estuche farmaceutico que comprende dicha vacuna |
| DE60239594D1 (de) | 2001-02-23 | 2011-05-12 | Glaxosmithkline Biolog Sa | Influenza vakzinzusammensetzungen zur intradermaler verabreichung |
| TWI228420B (en) | 2001-05-30 | 2005-03-01 | Smithkline Beecham Pharma Gmbh | Novel vaccine composition |
| WO2003105769A2 (en) | 2002-06-13 | 2003-12-24 | New York University | Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases |
| US7771726B2 (en) | 2003-10-08 | 2010-08-10 | New York University | Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases |
| KR20090051129A (ko) | 2004-04-05 | 2009-05-20 | 화이자 프로덕츠 인코포레이티드 | 미세유체화된 수중유 유화액 및 백신 조성물 |
| WO2005113756A1 (en) | 2004-05-14 | 2005-12-01 | Glaxosmithkline Biologicals S.A. | Method |
| JP2007537760A (ja) | 2004-05-20 | 2007-12-27 | アイディー バイオメディカル コーポレイション | インフルエンザワクチンを製造するためのプロセス |
| AU2005322353B2 (en) | 2004-12-23 | 2011-09-01 | Medimmune, Llc | Non-tumorigenic MDCK cell line for propagating viruses |
| GB0506001D0 (en) * | 2005-03-23 | 2005-04-27 | Glaxosmithkline Biolog Sa | Novel use |
| HUE027837T2 (en) * | 2005-03-23 | 2016-11-28 | Glaxosmithkline Biologicals Sa | Adjuvant use of influenza virus and oil-in-water emulsion to induce CD4 T-cell and / or enhanced B-cell cellular response |
| FR2884255B1 (fr) | 2005-04-11 | 2010-11-05 | Vivalis | Utilisation de lignees de cellules souches aviaires ebx pour la production de vaccin contre la grippe |
| US7691368B2 (en) | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
| US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
| TWI382019B (zh) | 2005-08-19 | 2013-01-11 | Array Biopharma Inc | 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯 |
| AU2006310171B2 (en) | 2005-11-01 | 2011-02-17 | Seqirus UK Limited | Cell-derived viral vaccines with low levels of residual cell DNA by beta-propiolactone treatment |
| CA2628158C (en) * | 2005-11-04 | 2015-12-15 | Novartis Vaccines And Diagnostics S.R.L. | Emulsions with free aqueous-phase surfactant as adjuvants for split influenza vaccines |
| FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
| WO2008005555A1 (en) | 2006-07-07 | 2008-01-10 | Gilead Sciences, Inc. | Modulators of toll-like receptor 7 |
| US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
| PT2086582E (pt) | 2006-10-12 | 2013-01-25 | Glaxosmithkline Biolog Sa | Vacina compreendendo uma emulsão adjuvante óleo em água |
| WO2008047174A1 (en) | 2006-10-18 | 2008-04-24 | Centre National De La Recherche Scientifique | Alpha-galactosylceramide analogs, their methods of manufacture, intermediate compounds useful in these methods, and pharmaceutical compositions containing them |
| JP2011506264A (ja) | 2006-12-06 | 2011-03-03 | ノバルティス アーゲー | インフルエンザウイルスの４つの株に由来する抗原を含むワクチン |
| PE20091236A1 (es) | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | Derivados de pirimidina como immunomoduladores de tlr7 |
| WO2009111337A1 (en) | 2008-03-03 | 2009-09-11 | Irm Llc | Compounds and compositions as tlr activity modulators |
| PT2276486E (pt) | 2008-03-24 | 2013-12-04 | 4Sc Discovery Gmbh | Novas imidazoquinolinas substituídas |
| EP2313111B1 (en) | 2008-08-01 | 2013-09-04 | Ventirx Pharmaceuticals, Inc. | Toll-like receptor agonist formulations and their use |
| AU2009333208A1 (en) * | 2008-12-16 | 2010-07-08 | Baxter Healthcare Sa | Production of influenza vaccines |
| WO2010136896A1 (en) * | 2009-05-29 | 2010-12-02 | Novartis Ag | Assays for influenza virus hemagglutinins |
| TWI445708B (zh) | 2009-09-02 | 2014-07-21 | Irm Llc | 作為ｔｌｒ活性調節劑之化合物及組合物 |
| GB0918830D0 (en) | 2009-10-27 | 2009-12-09 | Glaxosmithkline Biolog Niederl | Process |
| EA031379B1 (ru) | 2010-03-23 | 2018-12-28 | Новартис Аг | Соединения (липопептиды на основе цистеина) и композиции в качестве агонистов tlr2, применяемые для лечения инфекционных, воспалительных, респираторных и других заболеваний |
| ES2458355T3 (es) | 2010-09-01 | 2014-05-05 | Novartis Ag | Adsorción de inmunopotenciadores sobre sales metálicas insolubles |
| US20140335116A1 (en) | 2013-05-10 | 2014-11-13 | Novartis Ag | Avoiding narcolepsy risk in influenza vaccines |
-
2014
- 2014-05-12 US US14/275,373 patent/US20140335116A1/en not_active Abandoned
- 2014-05-12 CA CA2911296A patent/CA2911296A1/en not_active Abandoned
- 2014-05-12 AU AU2014264501A patent/AU2014264501A1/en not_active Abandoned
- 2014-05-12 CN CN201480039584.1A patent/CN105828835A/zh active Pending
- 2014-05-12 EP EP14167980.3A patent/EP2801372A3/en not_active Withdrawn
- 2014-05-12 JP JP2016512393A patent/JP2016521282A/ja active Pending
- 2014-05-12 SG SG11201509265SA patent/SG11201509265SA/en unknown
- 2014-05-12 MX MX2015015428A patent/MX2015015428A/es unknown
- 2014-05-12 BR BR112015028314A patent/BR112015028314A2/pt not_active Application Discontinuation
- 2014-05-12 KR KR1020157034963A patent/KR20160030097A/ko not_active Application Discontinuation
- 2014-05-12 WO PCT/EP2014/059672 patent/WO2014180999A1/en active Application Filing
-
2016
- 2016-10-04 US US15/284,624 patent/US20170216425A1/en not_active Abandoned
-
2019
- 2019-03-06 US US16/293,867 patent/US20190184007A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2014180999A1 (en) | 2014-11-13 |
| KR20160030097A (ko) | 2016-03-16 |
| AU2014264501A1 (en) | 2015-12-10 |
| MX2015015428A (es) | 2016-07-18 |
| CA2911296A1 (en) | 2014-11-13 |
| EP2801372A2 (en) | 2014-11-12 |
| US20170216425A1 (en) | 2017-08-03 |
| CN105828835A (zh) | 2016-08-03 |
| EP2801372A3 (en) | 2015-02-18 |
| US20140335116A1 (en) | 2014-11-13 |
| JP2016521282A (ja) | 2016-07-21 |
| US20190184007A1 (en) | 2019-06-20 |
| BR112015028314A2 (pt) | 2017-09-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL276210B1 (en) | Mers-cov vaccine | |
| IL279395A (en) | A vaccine | |
| HK1226440A1 (zh) | Cmv疫苗 | |
| HK1211224A1 (en) | Multivalent glycoconjugate vaccines | |
| HK1207967A1 (en) | Vaccine | |
| ZA201508642B (en) | Malaria vaccine | |
| GB201315946D0 (en) | Oncology vaccine | |
| GB201318084D0 (en) | Malaria vaccination | |
| EP2876161A4 (en) | VACCINE | |
| GB201223386D0 (en) | Vaccine | |
| GB201301085D0 (en) | Glycoconjugate Vaccine | |
| EP3022298A4 (en) | WAXED INFLUENZA VACCINE AND USES THEREOF | |
| ZA201409124B (en) | Reassortant btv and ahsv vaccines | |
| HK1217206A1 (zh) | 疫苗 | |
| SG11201509265SA (en) | Avoiding narcolepsy risk in influenza vaccines | |
| AP2015008615A0 (en) | Vaccines against pregnancy-associated malaria | |
| GB201301119D0 (en) | Viral vaccines | |
| ZA201508215B (en) | Avoiding narcolepsy risk in influenza vaccines | |
| GB201202090D0 (en) | Vaccine | |
| GB201320646D0 (en) | Vaccine | |
| GB201315556D0 (en) | Vaccine | |
| DK2846829T3 (en) | Vaccine combinations | |
| AP2014000880S (en) | Fan | |
| GB201217321D0 (en) | Vaccine | |
| GB201210226D0 (en) | Vaccine |